stockrowAbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.
- Revenue
- −76.3%
- EPS
- −50.0%
- Free cash flow
- +152.0%
Quarter to June 2026, against a year earlier
Follow ABCL
Alert me
AbCellera Biologics Inc. (ABCL) Total debt
AbCellera Biologics Inc.'s total debt at the end of fiscal 2022 was $83.0M, up 107.5% from $40.0M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $81.0M. Over the past ten years it has ranged from $3.4M (fiscal 2019) to $83.0M (fiscal 2022) — the current reading is the highest in ten years. AbCellera Biologics Inc. ranks 101st of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $83.0M | 107.50% |
| FY2021 | $40.0M | 471.43% |
| FY2020 | $7.0M | 103.31% |
| FY2019 | $3.4M | (13.92%) |
| FY2018 | $4.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $81.0M | (3.57%) |
| Jun 2023 | $84.0M | 1.20% |
| Mar 2023 | $83.0M | 0.00% |
| Dec 2022 | $83.0M | 7.79% |
| 11 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. compare | $109.4M |
| ABCL AbCellera Biologics Inc. | $81.0M |
| RLAY Relay Therapeutics, Inc. compare | $55.0M |
| ACAD ACADIA Pharmaceuticals Inc. compare | $48.1M |
| TNGX Tango Therapeutics, Inc. compare | $39.5M |
| XENE Xenon Pharmaceuticals Inc. compare | $11.0M |
| PBLS Parabilis Medicines, Inc. compare | $6.8M |
| EWTX Edgewise Therapeutics, Inc. compare | $5.6M |
| IOVA Iovance Biotherapeutics, Inc. compare | $1.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on ABCL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement